{"protocolSection": {"identificationModule": {"nctId": "NCT01357148", "orgStudyIdInfo": {"id": "0431A-235"}, "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Post Marketing Safety Study of Sitagliptin Phosphate/Metformin Hydrochloride (JANUMET\u00ae) (MK-0431A-235)", "officialTitle": "Sitagliptin Phosphate/Metformin HCl (JANUMET\u00ae) Post Marketing Surveillance Protocol"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "TERMINATED", "whyStopped": "Completion of MK-0431A-235 was rendered unnecessary, as the local oversight authority accepted in its stead the results of another study \\[MK-0431-234\\].", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-03"}, "primaryCompletionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-05-18", "studyFirstSubmitQcDate": "2011-05-19", "studyFirstPostDateStruct": {"date": "2011-05-20", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-02-01", "resultsFirstSubmitQcDate": "2012-02-01", "resultsFirstPostDateStruct": {"date": "2012-03-07", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-07", "lastUpdatePostDateStruct": {"date": "2015-08-10", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The primary objective of this study is to obtain safety information on the use of sitagliptin phosphate/metformin hydrochloride (HCl) (JANUMET\u00ae) from endocrinologists, diabetologists, internists, and general practitioners."}, "conditionsModule": {"conditions": ["Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"observationalModel": "COHORT", "timePerspective": "RETROSPECTIVE"}, "enrollmentInfo": {"count": 143, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Participants treated with sitagliptin phosphate/metformin HCl", "interventionNames": ["Drug: Sitagliptin Phosphate/Metformin HCl (JANUMET\u00ae)"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin Phosphate/Metformin HCl (JANUMET\u00ae)", "description": "Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET\u00ae) in routine clinical practice.", "armGroupLabels": ["Participants treated with sitagliptin phosphate/metformin HCl"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Number of Participants With an Adverse Event", "timeFrame": "Up to approximately 28 months"}, {"measure": "Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl", "timeFrame": "Up to approximately 28 months"}, {"measure": "Number of Participants With Concomitant Conditions", "timeFrame": "Up to approximately 28 months"}, {"measure": "Number of Participants Taking Concomitant Medications", "timeFrame": "Up to approximately 28 months"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Must be taking sitagliptin phosphate/metformin HCl (JANUMET\u00ae) for the treatment of type 2 diabetes mellitus\n* Treating physician must agree to provide information regarding the participant's treatment", "healthyVolunteers": false, "sex": "ALL", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"], "studyPopulation": "Participants with type 2 diabetes mellitus who are treated with sitagliptin phosphate/metformin HCl as per the standard of care in a physician's practice", "samplingMethod": "NON_PROBABILITY_SAMPLE"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This was a postmarketing, safety study of participants with Type 2 diabetes mellitus prescribed sitagliptin phosphate/metformin HCL (JANUMET\u00ae) in clinical practices in the Philippines from January 2009 to May 2010.", "groups": [{"id": "FG000", "title": "Sitagliptin Phosphate/Metformin HCl", "description": "Participants prescribed sitagliptin phosphate/metformin HCl in routine clinical practice."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "143"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "143"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin Phosphate/Metformin HCl", "description": "Participants prescribed sitagliptin phosphate/metformin HCl in routine clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "143"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51", "spread": "13.2"}]}]}]}, {"title": "Sex/Gender, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Female", "categories": [{"measurements": [{"groupId": "BG000", "value": "74"}]}]}, {"title": "Male", "categories": [{"measurements": [{"groupId": "BG000", "value": "66"}]}]}, {"title": "Unspecified", "categories": [{"measurements": [{"groupId": "BG000", "value": "3"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Number of Participants With an Adverse Event", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to approximately 28 months", "groups": [{"id": "OG000", "title": "Sitagliptin Phosphate/Metformin HCl", "description": "Participants prescribed sitagliptin phosphate/metformin HCl in routine clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}]}]}]}, {"type": "PRIMARY", "title": "Age of Participants Prescribed Sitagliptin Phosphate/Metformin HCl", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "years", "timeFrame": "Up to approximately 28 months", "groups": [{"id": "OG000", "title": "Sitagliptin Phosphate/Metformin HCl", "description": "Participants prescribed sitagliptin phosphate/metformin HCl in routine clinical practice."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "51", "spread": "13.2"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With Concomitant Conditions", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to approximately 28 months", "groups": [{"id": "OG000", "title": "Sitagliptin Phosphate/Metformin HCl"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "100"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Taking Concomitant Medications", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "Up to approximately 28 months", "groups": [{"id": "OG000", "title": "Sitagliptin Phosphate/Metformin HCl"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "143"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "86"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to approximately 28 months", "eventGroups": [{"id": "EG000", "title": "Sitagliptin Phosphate/Metformin HCl", "description": "Participants prescribed sitagliptin phosphate/metformin HCl in routine clinical practice.", "seriousNumAffected": 0, "seriousNumAtRisk": 143, "otherNumAffected": 0, "otherNumAtRisk": 143}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Carvedilol", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Dextromethorphan", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}